Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2001

View Archived Issues

Primary endpoint achieved in phase III trial of Gilead's adefovir dipivoxil for HBV

Use of PRAC protein in cancer Rx available for licensing from NIH

Licensing opportunity from NIH: new small RNAs as starting point for antibiotic development

Medicure presents drug with potential for healing ischemic injury

Protein Therapeutics begins phase II trial in juvenile RA

Medivir highlights pipeline progress for first half of 2001

Design of mixed direct thrombin and factor Xa inhibitors reported at ISTH

Antiplatelet antibody fragment designed at Chinese university

HTU-PA is a safe and effective thrombolytic agent in acute myocardial infarction

Beneficial effects of humanized anti-hTF antibody in hypercoagulable states

Safer anticoagulation obtained with Ro-67-8698, a new factor VIIa inhibitor, than napsagatran

MabCampath approved in Europe for B-CLL

Lilly Icos seeks European approval of Cialis for treatment of erectile dysfunction

Sea cucumber-based therapy useful for age-associated dementia

EMEA accepts Oxford GlycoSciences' MAA for Vevesca

Cangene halts pilot phase II trial of anti-HCV hyperimmune product

Protective effect demonstrated for FR-167653 against aspirin-induced gastric damage

FTY-720: effects on lymphocytes and in animal models of autoimmune diseases

Ramoplanin granted orphan drug status in Europe

EntreMed begins enrollment of initial patients in phase I/II study of rhEndostatin

Antithrombotic pentasaccharide covered extensively at recent scientific meeting

Inhibitors of PDE4 and use in asthma, allergies, etc.

Merck & Co. presents new pyrazinone thrombin inhibitors

Agents for HBV and HIV described in patent literature by Korean lab

Tie2 receptor kinase inhibitors useful for angiogenic disorders

Urotensin II analogues and pharmaceutical compositions for stroke and other disorders

Venlafaxine metabolite ethers with same pharmacological profile as venlafaxine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...